Ellevest Inc. Trims Stock Holdings in GSK plc (NYSE:GSK)

Ellevest Inc. cut its holdings in shares of GSK plc (NYSE:GSK) by 27.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 13,798 shares of the pharmaceutical company’s stock after selling 5,301 shares during the quarter. Ellevest Inc.’s holdings in GSK were worth $467,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Indiana Trust & Investment Management Co increased its stake in GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust acquired a new position in GSK in the 4th quarter valued at about $26,000. ST Germain D J Co. Inc. lifted its position in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares during the period. Sierra Ocean LLC purchased a new position in shares of GSK in the 4th quarter valued at approximately $32,000. Finally, Parkside Financial Bank & Trust raised its stake in shares of GSK by 470.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 818 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Down 0.7 %

GSK opened at $36.63 on Friday. The firm has a market cap of $75.58 billion, a P/E ratio of 23.04, a PEG ratio of 1.12 and a beta of 0.51. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The business’s fifty day simple moving average is $37.65 and its 200 day simple moving average is $36.00. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.93.

GSK (NYSE:GSK) last released its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The firm had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. During the same period in the prior year, the firm posted $0.43 earnings per share. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, equities research analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.60%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. GSK’s dividend payout ratio (DPR) is 86.60%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on GSK shares. BNP Paribas started coverage on shares of GSK in a research report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 price objective on the stock. Morgan Stanley started coverage on shares of GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Hsbc Global Res raised GSK to a “strong sell” rating in a report on Monday, April 28th. Finally, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.